Please login to the form below
Natpar
This page shows the latest Natpar news and features for those working in and with pharma, biotech and healthcare.
Shire finally bags EU approval for rare disease drug Natpar
Becomes first licenced treatment for hypoparathyroidism in Europe. Shire is celebrating an EU approval for its hypoparathyroidism treatment Natpar, two years after getting a green light for the drug in the ... US. Natpar - which is sold as Natpara in the
Latest news
-
Relief for Shire as FDA clears NPS' Natpara
If approved, the drug will be sold in the EU as Natpar.
-
Shire signs deal to buy NPS for $5.2bn
The drug could benefit from Shire's marketing muscle on both sides of the Atlantic, said Ornskov, and could soon be joined by Natpara/Natpar (recombinant parathyroid hormone) for the treatment
Relief for Shire as FDA clears NPS' Natpara
Shire signs deal to buy NPS for $5.2bn
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- bluebird bio gears up for split
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Lilly to target difficult-to-treat disease through tie-up with Lycia
- Sanofi/Regeneron bag first approval for Actemra rival sarilumab
PMHub
Graphite
Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
